JXR (01951) repurchased 2.1895 million shares on November 19 for HK$4.855 million.
JXR (01951) announced that on November 19, 2026, it spent HK$4.855 million to repurchase 2.1895 million shares.
JXR (01951) announced that on November 19, 2026, it repurchased 2.1895 million shares for HK$4.855 million.
Related Articles

Yinchuan Xinhua Commercial (600785.SH) has cumulatively repurchased 8.85% of its shares, spending approximately RMB300 million.

GRAND PHARMA (00512): Globally Innovative Nebulized Inhalant GPN01564 for the Treatment of Respiratory Syncytial Virus Approved to Initiate Phase I Clinical Study

Aotop Technology (688845.SH) IPO priced at RMB18.18 per share, subscription opens on November 23.
Yinchuan Xinhua Commercial (600785.SH) has cumulatively repurchased 8.85% of its shares, spending approximately RMB300 million.

GRAND PHARMA (00512): Globally Innovative Nebulized Inhalant GPN01564 for the Treatment of Respiratory Syncytial Virus Approved to Initiate Phase I Clinical Study

Aotop Technology (688845.SH) IPO priced at RMB18.18 per share, subscription opens on November 23.






